Exactech Earns FDA Clearance for Primary Knee Replacement System

TriVerse will be in limited launch starting in Q2 2023.

I Stock 1355436029

Exactech, a developer and producer of implants, instrumentation, and smart technologies for joint replacement surgery, announced today 510(k) clearance from the U.S. Food and Drug Administration to market the TriVerse primary knee system.

The TriVerse primary knee system is designed to accommodate surgical efficiency in hospitals and surgery centers alike, offering cruciate retaining, anterior stabilized and posterior stabilized constructs. Additionally, the TriVerse insert bearings will be exclusively available in highly crosslinked vitamin E-stabilized polyethylene.

TriVerse will launch with a compact set of adjustable mechanical instrumentation, with future compatibility planned with the company’s flagship ExactechGPS system.

The new system will add to the company’s portfolio of knee solutions, which includes its balanced knee system, award-winning primary and revision implants and instruments and fully integrated GPS platform.

TriVerse will be in limited launch starting in Q2 2023.

More in Orthopedic